Journal
NATURE
Volume 452, Issue 7187, Pages 646-U11Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/nature06778
Keywords
-
Categories
Funding
- NCI NIH HHS [R01 CA094184-02, R01 CA094184-04, R01 CA094184-03, R01 CA094184, R01 CA094184-01, R01 CA123031, R01 CA123031-01A2, R01 CA094184-05] Funding Source: Medline
Ask authors/readers for more resources
Tumour cells become addicted to the expression of initiating oncogenes like Ras, such that loss of oncogene expression in established tumours leads to tumour regression(1). HRas, NRas or KRas are mutated to remain in the active GTP- bound oncogenic state in many cancers(2). Although Ras activates several proteins to initiate human tumour growth, only PI3K, through activation of protein kinase B ( PKB; also known as AKT), must remain activated by oncogenic Ras to maintain this growth63. Here we show that blocking phosphorylation of the AKT substrate, endothelial nitric oxide synthase ( eNOS or NOS3), inhibits tumour initiation and maintenance. Moreover, eNOS enhances the nitrosylation and activation of endogenous wild- type Ras proteins, which are required throughout tumorigenesis. We suggest that activation of the PI3K - AKT - eNOS -( wild- type) Ras pathway by oncogenic Ras in cancer cells is required to initiate and maintain tumour growth.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available